I couldn't agree more. I don't like the chart, but the fundamentals are looking impressive. On balance, this is a cracking buy in my books. Baron
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling